Company / Free Cash Flow
NEKTAR THERAPEUTICS Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$208.7M
FY2025
5-year range
-$427.6M / -$193.5M
FY2021-FY2025
Trend
-7.9%
vs FY2024
Sector context
#152 of 194
Health Care
What the data says
NEKTAR THERAPEUTICS's free cash flow of -$209M is lower than 78% of companies in the Health Care sector (FY2025). Free Cash Flow has fluctuated over the past 10 years, ranging from -$428M in FY2023 to $704M in FY2020.
Based on SEC 10-K filings.
-$209M in FY2025.
Improved from -$428M to -$209M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 194This company -$208.7M Sector average $470.8M
▼
-144.3% below sector average
Key checks
Key Insights
- In FY2025, free cash flow decreased 7.9% year-over-year.
- Ranks #152 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2020.
- Lowest free cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -11.97 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$208.7M | -7.9% |
| FY2024 | -$193.5M | +54.8% |
| FY2023 | -$427.6M | -38.1% |
| FY2022 | -$309.7M | +27.6% |
| FY2021 | -$427.6M | -160.7% |
| FY2020 | $704.0M | +881.4% |
| FY2019 | -$90.1M | +27.0% |
| FY2018 | -$123.4M | -37.0% |
| FY2017 | -$90.1M | +40.7% |
| FY2016 | -$152.0M | -80.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026